Investigational drug · Phase 3
SYS6010
Not approved by FDA. In 15 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
15
15 still active
All registered trials
19
Any phase or sponsor naming "SYS6010"
First trial start
2025
Mar 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6010", any sponsor or status.
- Phase 311
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
- Locally Advanced/Metastatic/Recurrent ESCC
- Small Cell Lung Cancer
- Recurrent or Metastatic Breast Cancer
- Advanced Solid Tumors
- Non-small Cell Lung Cancer
- EGFR-mutated Locally Advanced or Metastatic NSCLC
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6010" as an intervention, largest first.
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Pivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07251062 · 737 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 30, 2029
Drug: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU); Investigator's choice of SOC and 1 more · For: Esophageal Squamous Cell Carcinoma
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07376382 · 680 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 12, 2026
Drug: SYS6010; Osimertinib and 1 more · For: NSCLC
- SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07472647 · 596 participants (planned) · Start Feb 28, 2026 · Primary completion Feb 28, 2029
Drug: SYS6090 + pemetrexed + platinum-based chemotherapy; SYS6090 + paclitaxel + platinum-based chemotherapy and 5 more · For: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07672223 · 586 participants (planned) · Start Jul 30, 2026 · Primary completion Sep 30, 2029
Drug: SYS6010; Enlonstobart and 5 more · For: Non-small Cell Lung Cancer
Sites: Shanghai, China · 2 sites in all
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07924111 · 585 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2029
Drug: SYS6010; SG001 and 2 more · For: Esophageal Squamous Cell Carcinoma
- SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase ⅢPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07442565 · 506 participants (planned) · Start Mar 10, 2026 · Primary completion Dec 30, 2027
Drug: SYS6010; Docetaxel · For: Non-Small Cell Lung Cancer
- SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)Pivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07633873 · 500 participants (planned) · Start Jun 2, 2026 · Primary completion Sep 30, 2027
Drug: SYS6010 injection; Enlonstobart injection and 2 more · For: Non-Small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07241936 · 444 participants (planned) · Start Nov 13, 2025 · Primary completion Oct 30, 2027
Drug: sirolimus (albumin-bound); DP303c and 3 more · For: Advanced Solid Tumors
Sites: Shanghai, China
- SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell CarcinomaPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07417735 · 436 participants (planned) · Start Mar 18, 2026 · Primary completion Dec 31, 2028
Drug: SYS6010; Investigator's Choice of Chemotherapy (Irinotecan hydrochloride,Paclitaxel,Docetaxel) · For: Locally Advanced/Metastatic/Recurrent ESCC
- A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal CarcinomaPivotal-lookingRecruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07925021 · 424 participants (planned) · Start Nov 6, 2026 · Primary completion Oct 1, 2029
Drug: SYS6010 combined with Enlonstobart; Tislelizumab combined with chemotherapy · For: Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery.
Liu L, Fei K, Wang J · Cancer Cell 2026
- SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.
Li ZM, Zhou Z, He ZY, et al. · Cancer Cell 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.